Cargando…
Lymphocyte reconstitution following autologous stem cell transplantation for progressive MS
BACKGROUND: Autologous stem cell transplantation (ASCT) for progressive multiple sclerosis (MS) may reset the immune repertoire. OBJECTIVE: The objective of this paper is to analyse lymphocyte recovery in patients with progressive MS treated with ASCT. METHODS: Patients with progressive MS not respo...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415040/ https://www.ncbi.nlm.nih.gov/pubmed/28607754 http://dx.doi.org/10.1177/2055217317700167 |
_version_ | 1783233456145170432 |
---|---|
author | Cull, G Hall, D Fabis-Pedrini, MJ Carroll, WM Forster, L Robins, F Ghassemifar, R Crosbie, C Walters, S James, I Augustson, B Kermode, AK |
author_facet | Cull, G Hall, D Fabis-Pedrini, MJ Carroll, WM Forster, L Robins, F Ghassemifar, R Crosbie, C Walters, S James, I Augustson, B Kermode, AK |
author_sort | Cull, G |
collection | PubMed |
description | BACKGROUND: Autologous stem cell transplantation (ASCT) for progressive multiple sclerosis (MS) may reset the immune repertoire. OBJECTIVE: The objective of this paper is to analyse lymphocyte recovery in patients with progressive MS treated with ASCT. METHODS: Patients with progressive MS not responding to conventional treatment underwent ASCT following conditioning with high-dose cyclophosphamide and antithymocyte globulin. Lymphocyte subset analysis was performed before ASCT and for two years following ASCT. Neurological function was assessed by the EDSS before ASCT and for three years post-ASCT. RESULTS: CD4+ T-cells fell significantly post-transplant and did not return to baseline levels. Recent thymic emigrants and naïve T-cells fell sharply post-transplant but returned to baseline by nine months and twelve months, respectively. T-regulatory cells declined post-transplant and did not return to baseline levels. Th1 and Th2 cells did not change significantly while Th17 cells fell post-transplant but recovered to baseline by six months. Neurological function remained stable in the majority of patients. Progression-free survival was 69% at three years. CONCLUSION: This study demonstrates major changes in the composition of lymphocyte subsets following ASCT for progressive MS. In particular, ablation and subsequent recovery of thymic output is consistent with the concept that ASCT can reset the immune repertoire in MS patients. |
format | Online Article Text |
id | pubmed-5415040 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-54150402017-06-12 Lymphocyte reconstitution following autologous stem cell transplantation for progressive MS Cull, G Hall, D Fabis-Pedrini, MJ Carroll, WM Forster, L Robins, F Ghassemifar, R Crosbie, C Walters, S James, I Augustson, B Kermode, AK Mult Scler J Exp Transl Clin Original Article BACKGROUND: Autologous stem cell transplantation (ASCT) for progressive multiple sclerosis (MS) may reset the immune repertoire. OBJECTIVE: The objective of this paper is to analyse lymphocyte recovery in patients with progressive MS treated with ASCT. METHODS: Patients with progressive MS not responding to conventional treatment underwent ASCT following conditioning with high-dose cyclophosphamide and antithymocyte globulin. Lymphocyte subset analysis was performed before ASCT and for two years following ASCT. Neurological function was assessed by the EDSS before ASCT and for three years post-ASCT. RESULTS: CD4+ T-cells fell significantly post-transplant and did not return to baseline levels. Recent thymic emigrants and naïve T-cells fell sharply post-transplant but returned to baseline by nine months and twelve months, respectively. T-regulatory cells declined post-transplant and did not return to baseline levels. Th1 and Th2 cells did not change significantly while Th17 cells fell post-transplant but recovered to baseline by six months. Neurological function remained stable in the majority of patients. Progression-free survival was 69% at three years. CONCLUSION: This study demonstrates major changes in the composition of lymphocyte subsets following ASCT for progressive MS. In particular, ablation and subsequent recovery of thymic output is consistent with the concept that ASCT can reset the immune repertoire in MS patients. SAGE Publications 2017-03-23 /pmc/articles/PMC5415040/ /pubmed/28607754 http://dx.doi.org/10.1177/2055217317700167 Text en © The Author(s) 2017 http://creativecommons.org/licenses/by-nc/3.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Article Cull, G Hall, D Fabis-Pedrini, MJ Carroll, WM Forster, L Robins, F Ghassemifar, R Crosbie, C Walters, S James, I Augustson, B Kermode, AK Lymphocyte reconstitution following autologous stem cell transplantation for progressive MS |
title | Lymphocyte reconstitution following autologous stem cell transplantation for progressive MS |
title_full | Lymphocyte reconstitution following autologous stem cell transplantation for progressive MS |
title_fullStr | Lymphocyte reconstitution following autologous stem cell transplantation for progressive MS |
title_full_unstemmed | Lymphocyte reconstitution following autologous stem cell transplantation for progressive MS |
title_short | Lymphocyte reconstitution following autologous stem cell transplantation for progressive MS |
title_sort | lymphocyte reconstitution following autologous stem cell transplantation for progressive ms |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415040/ https://www.ncbi.nlm.nih.gov/pubmed/28607754 http://dx.doi.org/10.1177/2055217317700167 |
work_keys_str_mv | AT cullg lymphocytereconstitutionfollowingautologousstemcelltransplantationforprogressivems AT halld lymphocytereconstitutionfollowingautologousstemcelltransplantationforprogressivems AT fabispedrinimj lymphocytereconstitutionfollowingautologousstemcelltransplantationforprogressivems AT carrollwm lymphocytereconstitutionfollowingautologousstemcelltransplantationforprogressivems AT forsterl lymphocytereconstitutionfollowingautologousstemcelltransplantationforprogressivems AT robinsf lymphocytereconstitutionfollowingautologousstemcelltransplantationforprogressivems AT ghassemifarr lymphocytereconstitutionfollowingautologousstemcelltransplantationforprogressivems AT crosbiec lymphocytereconstitutionfollowingautologousstemcelltransplantationforprogressivems AT walterss lymphocytereconstitutionfollowingautologousstemcelltransplantationforprogressivems AT jamesi lymphocytereconstitutionfollowingautologousstemcelltransplantationforprogressivems AT augustsonb lymphocytereconstitutionfollowingautologousstemcelltransplantationforprogressivems AT kermodeak lymphocytereconstitutionfollowingautologousstemcelltransplantationforprogressivems |